Immix Biopharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 17
- Market Cap
- $59.8M
- Website
- http://www.immixbio.com
- Introduction
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: IMX-110 combined with Tislelizumab
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Immix Biopharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05840835
- Locations
- 🇧🇷
Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo, Sao Paulo, Brazil
🇧🇷CIP Centro Integrado de Pesquisa / Hospital de Base / Fundação Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil
© Copyright 2025. All Rights Reserved by MedPath